Prescott Group Capital Management’s Endava DAVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$9.06M Buy
3,200,921
+1,608,367
+101% +$5.93M 0.78% 33
2026
Q1
$7.04M Sell
1,592,554
-13,770
-0.9% -$76K 0.7% 36
2025
Q4
$10.2M Buy
1,606,324
+389,970
+32% +$2.99M 0.94% 17
2025
Q3
$11.1M Buy
1,216,354
+609,215
+100% +$7.59M 1.17% 16
2025
Q2
$9.3M Buy
607,139
+315,000
+108% +$5.31M 1.1% 16
2025
Q1
$5.7M Sell
292,139
-119,000
-29% -$3.3M 0.83% 22
2024
Q4
$12.7M Buy
411,139
+69,135
+20% +$1.89M 1.72% 7
2024
Q3
$8.73M Sell
342,004
-12,012
-3% -$360K 1.27% 13
2024
Q2
$10.4M Buy
354,016
+53,969
+18% +$1.6M 1.62% 8
2024
Q1
$11.4M Buy
300,047
+265,000
+756% +$15.9M 1.83% 7
2023
Q4
$2.73M Buy
35,047
+16,699
+91% +$1.03M 0.48% 60
2023
Q3
$1.05M Buy
+18,348
New +$957K 0.23% 110

Other funds holding DAVA

Prescott Group Capital Management's DAVA Position: Q2 2026 in Review

Prescott Group Capital Management increased its Endava (DAVA) stake by 101% in Q2 2026, buying an estimated $5.93M and bringing the position to 3,200,921 shares worth $9.06M. The position accounts for 0.78% of the portfolio, ranked #33.

Prescott Group Capital Management first reported a position in DAVA in Q3 2023 and has held it in 12 quarters since. The position peaked at $12.7M in Q4 2024. 72 funds tracked by Wall St. Rank hold DAVA as of Q2 2026.

  • Prescott Group Capital Management held 3,200,921 shares of Endava worth $9.06M as of Q2 2026.
  • Prescott Group Capital Management bought 1,608,367 Endava shares in Q2 2026, an estimated $5.93M.
  • Endava made up 0.78% of Prescott Group Capital Management's portfolio in Q2 2026, its #33 holding.
  • Prescott Group Capital Management first reported a position in Endava in Q3 2023 and has held it in 12 quarters since.
  • Prescott Group Capital Management's Endava position peaked at $12.7M in Q4 2024.
  • 72 funds tracked by Wall St. Rank held Endava as of Q2 2026.

Based on Prescott Group Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.